1Clinical Research Unit, Mashhad University of Medical Sciences, Mashhad, Iran
2Department of NanoBiomedicine, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
The prevalence of the metabolic syndrome (MetS) and its various manifestations as a significant health epidemic is currently affecting populations of developed and developing countries worldwide. It is characterized by a group of metabolic abnormalities including central adiposity, insulin resistance, high blood pressure, glucose intolerance and dyslipidemia. Individuals with the MetS have the greater risk of developing major complications include Fatty liver, type 2 diabetes mellitus and cardiovascular diseases. Nuclear receptors are master regulators of gene transcription, often regulating several different metabolic pathways. Among them LXRα/β play a key role in regulation of lipogenesis, cholesterol/glucose homoeostasis and inﬂammatory pathways, via the induction/repression of target genes. Given the importance of lipid and carbohydrate metabolism and inflammation in the development of metabolic disorders, this mini-review focuses on the impact of the LXRs signaling on the risk of MetS and its related phenotypes with an emphasis on their potential therapeutic applications in treatment of MetS.